Program
bempedoic acid
Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Esperion Therapeutics | 200 open or running | phase 4since Aug 27, 2023 | Dec 16, 2010 | none ahead |
| Daiichi Sankyo | 61 open or running | phase 4since Apr 6, 2025 | Apr 6, 2025 | Jun 1, 2028phase 3 · NCT07474649 |
| Otsuka | 30 open or running | phase 3since Jan 4, 2023 | Mar 2, 2021 | none ahead |
| Humanis Saglık Anonim Sirketi | 20 open or running | phase 1since Apr 4, 2025 | Apr 4, 2025 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | phase 3since May 29, 2026 | May 29, 2026 | Jun 30, 2027phase 3 · NCT07623915 |
| Gan & Lee Pharmaceuticals | 10 open or running | phase 3since Jan 13, 2025 | Jan 13, 2025 | none ahead |
Also a collaborator on its studies: medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Dec 16, 2010.
- Jun 19, 2017Phase 2 study in HypercholesterolemiaEsperion Therapeutics · NCT03193047 · 59 enrolled · United States
- Nov 6, 2017Phase 3 study in HyperlipidemiasEsperion Therapeutics · NCT03337308 · 382 enrolled · United States
- Mar 2, 2021Otsuka's first study: phase 2 study in HypercholesterolemiaNew to OtsukaOtsuka · NCT04784442 · 188 enrolled · Japan
- Jan 4, 20232 phase 3 studies in Hyper-low-density Lipoprotein (LDL) CholesterolemiaOtsuka · NCT05687071, NCT05683340
- Jan 12, 2023Phase 2 study in HypercholesterolemiaEsperion Therapeutics · NCT05694260 · 31 enrolled · United States, Canada, Denmark and more
- Aug 27, 2023Phase 4 study in Healthy Lactating WomenEsperion Therapeutics · NCT06021951 · 16 enrolled · United States
- Jan 13, 2025Gan & Lee Pharmaceuticals's first study: phase 3 study in HyperlipidemiasNew to Gan & Lee PharmaceuticalsGan & Lee Pharmaceuticals · NCT06780410 · 245 enrolled · China
- Apr 4, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in HypercholesterolemiaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06923956 · 14 enrolled · India
- Apr 6, 2025Daiichi Sankyo's first study: phase 4 study in Hyperlipoproteinemia Type IINew to Daiichi SankyoDaiichi Sankyo · NCT06925100 · 180 enrolled · Taiwan
- Sep 5, 2025Phase 1 study in HypercholesterolemiaHumanis Saglık Anonim Sirketi · NCT07170852 · 32 enrolled · India
- Sep 11, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07182383, NCT07201545
- Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
- Mar 11, 2026Phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649 · 103 planned · Germany, Italy, Spain
- May 29, 2026CSPC Pharmaceutical Group's first study: phase 3 study in Primary HyperlipidemiaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07623915 · 222 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Primary HyperlipidemiaCSPC Pharmaceutical Group · NCT07623915
- Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649
TargetBeta
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07623915Primary Hyperlipidemia | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2027 | 222 |
| NCT07474649Coronary Artery Disease · Germany, Italy, Spain | 3 | Not yet recruiting | Daiichi Sankyo | Jun 1, 2028 | 103 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Jan 28, 2026 | 58 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Nov 24, 2025 | 58 |
| NCT07170852Hypercholesterolemia · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jun 16, 2025 | 32 |
| NCT06925100Hyperlipoproteinemia Type II · Taiwan | 4 | Completed | Daiichi Sankyo | Oct 15, 2025 | 180 |
| NCT06923956Hypercholesterolemia · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Dec 18, 2024 | 14 |
| NCT06780410Hyperlipidemias · China | 3 | Completed | Gan & Lee Pharmaceuticals | Aug 5, 2025 | 245 |
| NCT06021951Healthy Lactating Women · United States | 4 | Completed | Esperion Therapeutics | Feb 21, 2024 | 16 |
| NCT05694260Hypercholesterolemia · United States, Canada, Denmark and more | 2 | Completed | Esperion Therapeutics | Jun 4, 2025 | 31 |
| NCT05687071Hyper-low-density Lipoprotein (LDL) Cholesterolemia · Japan | 3 | Completed | Otsuka | Oct 5, 2024 | 130 |
| NCT05683340Hyper-low-density Lipoprotein (LDL) Cholesterolemia · Japan | 3 | Completed | Otsuka | Feb 20, 2024 | 96 |
| NCT04784442Hypercholesterolemia · Japan | 2 | Completed | Otsuka | Apr 18, 2022 | 188 |
| NCT03337308Hyperlipidemias · United States | 3 | Completed | Esperion Therapeutics | Jun 18, 2018 | 382 |
| NCT03193047Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Jan 29, 2018 | 59 |
| NCT03067441Hypercholesterolemia · United States | 3 | Completed | Esperion Therapeutics | Nov 5, 2019 | 1,462 |
| NCT03051100Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Jun 1, 2017 | 63 |
| NCT03001076Hypercholesterolemia · United States | 3 | Completed | Esperion Therapeutics | Jan 11, 2018 | 269 |
| NCT02993406Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Completed | Esperion Therapeutics | Nov 7, 2022 | 13,970 |
| NCT02991118Hypercholesterolemia · United States | 3 | Completed | Esperion Therapeutics | Aug 22, 2018 | 779 |
| NCT02988115Hypercholesterolemia · United States, Canada | 3 | Completed | Esperion Therapeutics | Mar 16, 2018 | 345 |
| NCT02666664Hypercholesterolemia · United States, Canada, Germany and more | 3 | Completed | Esperion Therapeutics | Feb 21, 2018 | 2,230 |
| NCT02659397Hyperlipidemias · United States | 2 | Completed | Esperion Therapeutics | Jul 2016 | 68 |
| NCT02178098Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | May 22, 2015 | 143 |
| NCT02072161Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Jan 2015 | 133 |
| NCT01941836Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Oct 2014 | 349 |
| NCT01779453Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Aug 2013 | 58 |
| NCT01751984Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | May 1, 2013 | 56 |
| NCT01607294Hyperlipidemias · United States | 2 | Completed | Esperion Therapeutics | Oct 2012 | 60 |
| NCT01485146Safety Evaluation of Escalating Doses · United States | 1 | Completed | Esperion Therapeutics | Jan 25, 2012 | 24 |
| NCT01262638Dyslipidemias · United States | 2 | Completed | Esperion Therapeutics | Aug 23, 2011 | 177 |
How it is read
Names in the registry
- “ETC-1002”, 10 entries
- “Bempedoic acid”, 7 entries
- “180mg of ETC-1002(bempedoic acid)”, 3 entries
- “bempedoic acid”, 3 entries
- “Bempedoic Acid Tablet”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 16 studies
- Hyperlipidemias, 5 studies
- Dyslipidemias, 2 studies
- Coronary Artery Disease, 1 study
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.